Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1963 3
1964 4
1966 3
1968 1
1969 2
1970 2
1971 5
1973 2
1974 1
1975 2
1977 1
1978 3
1979 5
1980 7
1981 11
1982 4
1983 4
1984 7
1985 6
1986 3
1987 5
1988 6
1989 6
1990 5
1991 4
1992 5
1993 4
1994 3
1995 2
1996 2
1997 5
1998 3
1999 11
2000 5
2001 5
2002 5
2003 3
2004 8
2005 4
2006 6
2007 9
2008 6
2009 3
2010 6
2011 4
2012 8
2013 5
2014 5
2015 6
2016 6
2017 7
2018 2
2019 6
2020 2
2022 3
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

236 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "steoroids"
Page 1
Cushing's syndrome.
Howlett TA, Rees LH, Besser GM. Howlett TA, et al. Clin Endocrinol Metab. 1985 Nov;14(4):911-45. doi: 10.1016/s0300-595x(85)80083-9. Clin Endocrinol Metab. 1985. PMID: 3002679 Review.
Cushing's disease is caused in the majority of cases by basophil pituitary microadenomas which may be successfully treated by trans-sphenoidal hypophysectomy. Treatment with metyrapone or o,p'-DDD can always induce a clinical remission but not a cure, and neu …
Cushing's disease is caused in the majority of cases by basophil pituitary microadenomas which may be successfully treated by trans-sphenoid …
Mitotane (o,p'-DDD).
Gutierrez ML, Crooke ST. Gutierrez ML, et al. Cancer Treat Rev. 1980 Mar;7(1):49-55. doi: 10.1016/s0305-7372(80)80025-9. Cancer Treat Rev. 1980. PMID: 7397707 No abstract available.
Adrenocortical carcinoma. Our experience.
Favia G, Lumachi F, Carraro P, D'Amico DF. Favia G, et al. Minerva Endocrinol. 1995 Mar;20(1):95-9. Minerva Endocrinol. 1995. PMID: 7651289 Review.
Seventeen patients underwent surgery, and two had multiple CT-FNAB-confirmed liver metastases and received o,p'DDD and chemotherapy treatment only. Tumor staging was the following: 3 (16%) stage I patients (tumor size varying from 4 to 5 cm), 7 …
Seventeen patients underwent surgery, and two had multiple CT-FNAB-confirmed liver metastases and received o,p'DDD and …
Management of adrenocortical carcinoma.
Allolio B, Hahner S, Weismann D, Fassnacht M. Allolio B, et al. Clin Endocrinol (Oxf). 2004 Mar;60(3):273-87. doi: 10.1046/j.1365-2265.2003.01881.x. Clin Endocrinol (Oxf). 2004. PMID: 15008991 Review.
Adrenocortical carcinoma (ACC) is a rare neoplasm with poor prognosis. Patients present with signs of steroid hormone excess (e.g. Cushing's syndrome, virilization) or an abdominal mass. ...In metastatic disease (stage IV ACC) not amenable to surgery mitotane (o, …
Adrenocortical carcinoma (ACC) is a rare neoplasm with poor prognosis. Patients present with signs of steroid hormone excess (e.g. Cu …
Characterization of mitotane (o,p'-DDD)--cyclodextrin inclusion complexes: phase-solubility method and NMR.
Alfonsi R, Attivi D, Astier A, Socha M, Morice S, Gibaud S. Alfonsi R, et al. Ann Pharm Fr. 2013 May;71(3):186-92. doi: 10.1016/j.pharma.2013.02.001. Epub 2013 Mar 15. Ann Pharm Fr. 2013. PMID: 23622697
Mitotane (o,p'-dichlorodimethyl dichloroethane [o,p'-DDD]) is used for the treatment of adrenocortical cancer and occasionally Cushing's syndrome. ...The inclusion of mitotane in methyl-ss-cyclodextrins was studied using both phase-solubility methods a …
Mitotane (o,p'-dichlorodimethyl dichloroethane [o,p'-DDD]) is used for the treatment of adrenocortical cancer an …
Sex-Based Evaluation of Lipid Profile in Postoperative Adjuvant Mitotane Treatment for Adrenocortical Carcinoma.
Allegra S, Puglisi S, Borin C, Chiara F, Basile V, Calabrese A, Reimondo G, De Francia S. Allegra S, et al. Biomedicines. 2022 Aug 3;10(8):1873. doi: 10.3390/biomedicines10081873. Biomedicines. 2022. PMID: 36009421 Free PMC article.
Methods: A chromatographic method was used to quantify the drug in plasma collected from adult patients with complete tumor resection, also considering active metabolite o,p'-DDE. Results: We observed different lipid profiles between males and females and between pre- and …
Methods: A chromatographic method was used to quantify the drug in plasma collected from adult patients with complete tumor resection …
The distribution of o,p'-DDD (mitotane) among serum lipoproteins in normo- and hypertriglyceridemia.
Gebhardt DO, Moolenaar AJ, van Seters AP, van der Velde EA, Gevers Leuven JA. Gebhardt DO, et al. Cancer Chemother Pharmacol. 1992;29(4):331-4. doi: 10.1007/BF00685956. Cancer Chemother Pharmacol. 1992. PMID: 1537084
We found that the distribution of the lipophilic chemotherapeutic agent o,p'-DDD (mitotane) among serum (lipo)proteins was altered in hypertriglyceridemia, with relatively more o,p'-DDD accumulating in the chylomicron and very-low-density …
We found that the distribution of the lipophilic chemotherapeutic agent o,p'-DDD (mitotane) among serum (lipo)proteins …
Mitotane treatment for adrenocortical carcinoma: an overview.
De Francia S, Ardito A, Daffara F, Zaggia B, Germano A, Berruti A, Di Carlo F. De Francia S, et al. Minerva Endocrinol. 2012 Mar;37(1):9-23. Minerva Endocrinol. 2012. PMID: 22382612 Review.
Adrenocortical carcinoma (ACC) is a rare aggressive endocrine neoplasm characterized by a 5-year survival of less than 50%. ...Complete surgical resection is the only potentially curative treatment for patients with localized disease; however, due to a recurrence rate of 5 …
Adrenocortical carcinoma (ACC) is a rare aggressive endocrine neoplasm characterized by a 5-year survival of less than 50%. ...Comple …
Adrenocortical carcinoma.
Decker RA, Kuehner ME. Decker RA, et al. Am Surg. 1991 Aug;57(8):502-13. Am Surg. 1991. PMID: 1928992
The first patient underwent resection of recurrent tumor on two occasions in addition to receiving o,p'-DDD and survived 84 months. ...It is concluded that resection for local recurrence may prolong survival and that significant and lasting tumor …
The first patient underwent resection of recurrent tumor on two occasions in addition to receiving o,p'-DDD and …
o,p'-DDT and its metabolites inhibit progesterone-dependent responses in yeast and human cells.
Klotz DM, Ladlie BL, Vonier PM, McLachlan JA, Arnold SF. Klotz DM, et al. Mol Cell Endocrinol. 1997 Apr 25;129(1):63-71. doi: 10.1016/s0303-7207(96)04041-5. Mol Cell Endocrinol. 1997. PMID: 9175630
In transactivation assays using both yeast and T47D cells, o,p'-DDT and the metabolites p,p'-DDT, o,p'-DDD, p,p'-DDD, o,p'-DDE, p,p'-DDE, p,p'-DDA, and DDOH inhibited progesterone-induced reporter gene activity in a dose-dependent manner. ...Our result …
In transactivation assays using both yeast and T47D cells, o,p'-DDT and the metabolites p,p'-DDT, o,p'-DDD, p,p'-DDD, o …
236 results